Pharmacokinetics of Oxypurinol in Patients on Dialysis

Not Applicable

Completed

• Conditions: Gout; Renal impairment; Inflammatory and Immune System - Other inflammatory or immune system disorders; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12614000328673
• Lead Sponsor: Professor Lisa Stamp

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-03-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Patients must be receiving haemodialysis, must be diagnosed with gout, and must be already receiving 100mg of allopurinol daily.

Exclusion Criteria

No exclusion criteria.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Allopurinol and oxypurinol plasma area under the concentration time curves (trend across time in concentration). Laboratory analysis of the blood samples taken will be used to determine blood concentrations of allopurinol and oxypurinol, and area under the curve concentrations will be calculated using the trapezoidal method.[0 - 48 hours from dialysis commencement]

Secondary Outcome Measures

Name	Time	Method
Peak and trough concentrations at steady state will be assessed via laboratory analysis of the blood samples taken.[0 - 48 hours from dialysis commencement]